|
Aug 12
|
William Blair Remains Bullish on Genmab A/S (GMAB)
|
|
Aug 8
|
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
|
|
Aug 8
|
Epkinly breaks ground in Phase III FL trial
|
|
Aug 8
|
Genmab AS (GMAB) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Advancements
|
|
Aug 7
|
Genmab raises full-year outlook, shares rise
|
|
Aug 7
|
Genmab Announces Financial Results for the First Half of 2025
|
|
Aug 7
|
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
|
|
Aug 4
|
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
|
|
Aug 1
|
GMAB vs. ACAD: Which Stock Is the Better Value Option?
|
|
Jul 29
|
Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More
|
|
Jul 28
|
TD Cowen Maintains a Hold on Genmab A/S (GMAB)
|
|
Jul 26
|
Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
|
|
Jul 25
|
Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook
|
|
Jul 24
|
iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
|
|
Jul 22
|
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
|
|
Jul 22
|
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
|
|
Jun 16
|
Genmab announces Phase Ib/II trial outcomes of epcoritamab combo for DLBCL
|
|
Jun 15
|
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
|
|
Apr 10
|
Genmab A/S Share Capital Reduction
|
|
Apr 7
|
Transactions In Connection with Share Buy-back Program
|